1
|
Senent Y, Fresquet V, Jimenez V, Valencia K, Remirez A, Exposito F, Gonzalez-Huarriz M, de Cordoba BRF, Moreno H, Ajona D, Alonso MM, Lecanda F, Pineda-Lucena A, Prosper F, Calvo A, Martinez-Climent JA, Pio R. Abstract 5117: Combined treatment with the epigenetic drug CM272 and an anti-BCL-XL proapoptotic drug sensitizes solid tumors to immune checkpoint blockade. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-5117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Epigenetic modulators in combination with proapoptotic drugs have become a standard of treatment for acute myeloid leukemia. However, the clinical efficacy of these combinations in solid tumors has shown to be negligible. Our group has demonstrated that the epigenetic drug CM272, which targets DNMT and G9a, induces synergistic responses in combination with proapoptotic drugs in hematological malignancies (Cancer Discovery 2021). We have also reported that CM272 induces an immunogenic cell death that sensitizes tumor cells to immune checkpoint blockade (ICB) (Nature Medicine 2020). Here, we hypothesized that CM272 in combination with proapoptotic drugs may sensitize tumor cells to ICB, resulting in profound anti-tumor responses. To test this hypothesis, we evaluated in vitro the sensitivity of cancer cells to different combinations of epigenetic and proapoptotic drugs. The most efficient combination was tested in various immunocompetent mouse models, followed by an immunophenotypic characterization of the tumor microenvironment. We found that CM272 in combination with inhibitors of BCL-XL, BCL2 or MCL1, yielded synergistic in vitro responses in a large collection of human and mouse cell lines derived from solid tumors. Mechanistically, the treatments induced the expression of endogenous retroelements/retroviruses, which led to the activation of RIG-1 and MDA5 viral sensors, ATP hydrolysis and tumor cell death. Remarkably, we found that CM272 in combination with BCL-XL inhibition had more potent anti-tumor effects than that found with BCL2 or MCL1 inhibitors. In vivo, the triple combination CM272, A1331852 (BCL-XL inhibitor) and an anti-PD-1 moAb significantly reduced tumor growth and increased overall survival in three subcutaneous lung cancer models (LLC, 393P, Lacun-3) in comparison to double treatments. Moreover, this triple combination also induced significant anti-tumor responses in subcutaneous mouse models of colon cancer (MC38) and melanoma (B16), as well as in orthotopic models of lung cancer (LLC), glioblastoma (CT-2A) and breast cancer (ANV5), leading to prolonged survival and cure in a fraction of animals. The triple therapy was associated with a significant increase in the ratio of CD8 T versus immunosuppressive Treg cells, and M1 versus M2 macrophages. In conclusion, we report a novel regimen combining a dual epigenetic inhibitor, an anti-BCL-XL, and an anti-PD-1 moAb that results in potent responses in multiple pre-clinical models of solid tumors. The mechanisms underneath the antitumor responses include the modulation of the energy metabolism in tumor cells, leading to cell death boosted by an anti-BCL-XL pro-apoptotic drug, along with fostering the immune system to generate an efficient anti-tumor response assisted by ICB. This study reveals the potential of epigenetic therapeutics to treat and cure patients with solid tumors.
Citation Format: Yaiza Senent, Vicente Fresquet, Victoria Jimenez, Karmele Valencia, Ana Remirez, Francisco Exposito, Marisol Gonzalez-Huarriz, Borja Ruiz-Fernandez de Cordoba, Haritz Moreno, Daniel Ajona, Marta M Alonso, Fernando Lecanda, Antonio Pineda-Lucena, Felipe Prosper, Alfonso Calvo, Jose Angel Martinez-Climent, Ruben Pio. Combined treatment with the epigenetic drug CM272 and an anti-BCL-XL proapoptotic drug sensitizes solid tumors to immune checkpoint blockade. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5117.
Collapse
Affiliation(s)
- Yaiza Senent
- 1Center for Applied Medical Research (CIMA)-University of Navarra, Pamplona, Spain
| | - Vicente Fresquet
- 1Center for Applied Medical Research (CIMA)-University of Navarra, Pamplona, Spain
| | - Victoria Jimenez
- 1Center for Applied Medical Research (CIMA)-University of Navarra, Pamplona, Spain
| | - Karmele Valencia
- 1Center for Applied Medical Research (CIMA)-University of Navarra, Pamplona, Spain
| | - Ana Remirez
- 1Center for Applied Medical Research (CIMA)-University of Navarra, Pamplona, Spain
| | | | | | | | - Haritz Moreno
- 1Center for Applied Medical Research (CIMA)-University of Navarra, Pamplona, Spain
| | - Daniel Ajona
- 1Center for Applied Medical Research (CIMA)-University of Navarra, Pamplona, Spain
| | - Marta M Alonso
- 1Center for Applied Medical Research (CIMA)-University of Navarra, Pamplona, Spain
| | - Fernando Lecanda
- 1Center for Applied Medical Research (CIMA)-University of Navarra, Pamplona, Spain
| | | | - Felipe Prosper
- 1Center for Applied Medical Research (CIMA)-University of Navarra, Pamplona, Spain
| | - Alfonso Calvo
- 1Center for Applied Medical Research (CIMA)-University of Navarra, Pamplona, Spain
| | | | - Ruben Pio
- 1Center for Applied Medical Research (CIMA)-University of Navarra, Pamplona, Spain
| |
Collapse
|
2
|
Ruiz-Fernandez de Cordoba B, Moreno H, Valencia K, Perurena N, Ruedas P, Walle T, Pezonaga-Torres A, Hinojosa J, Guruceaga E, Pineda-Lucena A, Abengozar-Muela M, Cochonneau D, Zandueta C, Martinez-Canarias S, Teijeira A, Ajona D, Ortiz-Espinosa S, Morales X, Ortiz de Solorzano C, Santisteban M, Ramos-Garcia LI, Guembe L, Strnad V, Heymann D, Hervas-Stubbs S, Pio R, Rodriguez-Ruiz ME, de Andrea CE, Vicent S, Melero I, Lecanda F, Martinez-Monge R. Tumor ENPP1(CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer. Cancer Discov 2022; 12:1356-1377. [PMID: 35086922 DOI: 10.1158/2159-8290.cd-21-0932] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Revised: 11/15/2021] [Accepted: 01/18/2022] [Indexed: 11/16/2022]
Abstract
Locoregional failure (LRF) in breast cancer patients post-surgery and post-irradiation (IR) is linked to a dismal prognosis. In a refined new model, we identified Enpp1 (Ectonucleotide pyrophosphatase /phosphodiesterase 1/CD203a) to be closely associated with LRF. Enpp1high circulating tumor cells (CTC) contribute to relapse by a self-seeding mechanism. This process requires the infiltration of PMN-MDSC and neutrophil extracellular traps (NET) formation. Genetic and pharmacological Enpp1 inhibition or NET blockade extend relapse-free survival. Furthermore, in combination with fractionated irradiation (FD), Enpp1 abrogation obliterates LRF. Mechanistically, Enpp1-generated adenosinergic metabolites enhance Haptoglobin (Hp) expression. This inflammatory mediator elicits myeloid invasiveness and promotes NET formation. Accordingly, a significant increase in ENPP1 and NET formation is detected in relapsed human breast cancer tumors. Moreover, high ENPP1 or HP levels are associated with poor prognosis. These findings unveil the ENPP1/HP axis as an unanticipated mechanism exploited by tumor cells linking inflammation to immune remodeling favoring local relapse.
Collapse
Affiliation(s)
| | - Haritz Moreno
- Program in Solid Tumors and Biomarkers, Center for Applied Medical Research (CIMA), University of Navarra
| | - Karmele Valencia
- Oncology, Center for Applied Medical Research (CIMA), University of Navarra
| | - Naiara Perurena
- Medicine, Genetics Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School
| | - Pablo Ruedas
- Solid Tumors. Oncology Division, Center for Applied Medical Research (CIMA), University of Navarra
| | - Thomas Walle
- Clinical Cooperation Unit Molecular Radiooncology, German Cancer Research Center
| | - Alberto Pezonaga-Torres
- Solid Tumors. Oncology Division, Center for Applied Medical Research (CIMA), University of Navarra
| | - Juan Hinojosa
- Solid Tumors. Oncology Division, Center for Applied Medical Research (CIMA), University of Navarra
| | | | - Antonio Pineda-Lucena
- Program of Advanced Therapies, Center for Applied Medical Research (CIMA), University of Navarra
| | - Marta Abengozar-Muela
- Pathology, University of Navarra and Instituto de Investigacion Sanitaria de Navarra (IdISNA)
| | | | | | - Susana Martinez-Canarias
- Solid Tumors. Oncology Division, Center for Applied Medical Research (CIMA), University of Navarra
| | - Alvaro Teijeira
- Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra and Instituto de Investigacion Sanitaria de Navarra (IdISNA)
| | - Daniel Ajona
- Center for Applied Medical Research (CIMA), University of Navarra
| | - Sergio Ortiz-Espinosa
- Program in Solid Tumors and Biomarkers, Center for Applied Medical Research (CIMA), University of Navarra
| | - Xabier Morales
- Preclinical Models and Analysis Tools, Center for Applied Medical Research (CIMA), University of Navarra
| | | | | | | | - Laura Guembe
- Morphology Core Facility, Center for Applied Medical Research (CIMA), University of Navarra
| | | | - Dominique Heymann
- CNRS, US2B, UMR 6286, Tumour Heterogenetity and Precision Medicine, Nantes Universit�
| | - Sandra Hervas-Stubbs
- Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra
| | - Ruben Pio
- Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra
| | - Maria E Rodriguez-Ruiz
- Department of Oncology, University Clinic, University of Navarra and Instituto de Investigacion Sanitaria de Navarra (IdISNA)
| | | | - Silvestre Vicent
- Program of Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra
| | - Ignacio Melero
- Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra and Instituto de Investigacion Sanitaria de Navarra (IdISNA)
| | - Fernando Lecanda
- Solid Tumors. Oncology Division, Center for Applied Medical Research (CIMA), University of Navarra
| | | |
Collapse
|
3
|
Vallejo A, Erice O, Entrialgo-Cadierno R, Feliu I, Guruceaga E, Perugorria MJ, Olaizola P, Muggli A, Macaya I, O'Dell M, Ruiz-Fernandez de Cordoba B, Ortiz-Espinosa S, Hezel AF, Arozarena I, Lecanda F, Avila MA, Fernandez-Barrena MG, Evert M, Ponz-Sarvise M, Calvisi DF, Banales JM, Vicent S. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. J Hepatol 2021; 75:363-376. [PMID: 33887357 DOI: 10.1016/j.jhep.2021.03.028] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/30/2020] [Revised: 03/10/2021] [Accepted: 03/25/2021] [Indexed: 01/27/2023]
Abstract
BACKGROUND & AIMS Cholangiocarcinoma (CCA) is a neoplasia of the biliary tract driven by genetic, epigenetic and transcriptional mechanisms. Herein, we investigated the role of the transcription factor FOSL1, as well as its downstream transcriptional effectors, in the development and progression of CCA. METHODS FOSL1 was investigated in human CCA clinical samples. Genetic inhibition of FOSL1 in human and mouse CCA cell lines was performed in in vitro and in vivo models using constitutive and inducible short-hairpin RNAs. Conditional FOSL1 ablation was done using a genetically engineered mouse (GEM) model of CCA (mutant KRAS and Trp53 knockout). Follow-up RNA and chromatin immunoprecipitation (ChIP) sequencing analyses were carried out and downstream targets were validated using genetic and pharmacological inhibition. RESULTS An inter-species analysis of FOSL1 in CCA was conducted. First, FOSL1 was found to be highly upregulated in human and mouse CCA, and associated with poor patient survival. Pharmacological inhibition of different signalling pathways in CCA cells converged on the regulation of FOSL1 expression. Functional experiments showed that FOSL1 is required for cell proliferation and cell cycle progression in vitro, and for tumour growth and tumour maintenance in both orthotopic and subcutaneous xenograft models. Likewise, FOSL1 genetic abrogation in a GEM model of CCA extended mouse survival by decreasing the oncogenic potential of transformed cholangiocytes. RNA and ChIP sequencing studies identified direct and indirect transcriptional effectors such as HMGCS1 and AURKA, whose genetic and pharmacological inhibition phenocopied FOSL1 loss. CONCLUSIONS Our data illustrate the functional and clinical relevance of FOSL1 in CCA and unveil potential targets amenable to pharmacological inhibition that could enable the implementation of novel therapeutic strategies. LAY SUMMARY Understanding the molecular mechanisms involved in cholangiocarcinoma (bile duct cancer) development and progression stands as a critical step for the development of novel therapies. Through an inter-species approach, this study provides evidence of the clinical and functional role of the transcription factor FOSL1 in cholangiocarcinoma. Moreover, we report that downstream effectors of FOSL1 are susceptible to pharmacological inhibition, thus providing new opportunities for therapeutic intervention.
Collapse
Affiliation(s)
- Adrián Vallejo
- University of Navarra, Centre for Applied Medical Research, Program in Solid Tumours, Pamplona, Spain
| | - Oihane Erice
- University of Navarra, Centre for Applied Medical Research, Program in Solid Tumours, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | | | - Iker Feliu
- University of Navarra, Centre for Applied Medical Research, Program in Solid Tumours, Pamplona, Spain
| | - Elizabeth Guruceaga
- IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; University of Navarra, Centre for Applied Medical Research, Computational Biology Program, Pamplona, Spain; ProteoRed-Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - Maria J Perugorria
- University of the Basque Country, San Sebastian, Spain; Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute - Donostia University Hospital -, University of the Basque Country (UPV/EHU), San Sebastian, Spain; National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), Spain
| | - Paula Olaizola
- Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute - Donostia University Hospital -, University of the Basque Country (UPV/EHU), San Sebastian, Spain
| | - Alexandra Muggli
- Institute of Pathology, University of Regensburg, Regensburg, Germany
| | - Irati Macaya
- University of Navarra, Centre for Applied Medical Research, Program in Solid Tumours, Pamplona, Spain
| | - Michael O'Dell
- University of Rochester Medical Centre, Rochester, NY, USA
| | | | - Sergio Ortiz-Espinosa
- University of Navarra, Centre for Applied Medical Research, Program in Solid Tumours, Pamplona, Spain
| | - Aram F Hezel
- University of Rochester Medical Centre, Rochester, NY, USA
| | - Imanol Arozarena
- IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; Cancer Signalling Unit, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), Pamplona, Spain
| | - Fernando Lecanda
- University of Navarra, Centre for Applied Medical Research, Program in Solid Tumours, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC, Instituto de Salud Carlos III), Madrid, Spain; University of Navarra, Department of Pathology, Anatomy and Physiology, Pamplona, Spain
| | - Matias A Avila
- IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), Spain; University of Navarra, Centre for Applied Medical Research, Hepatology Program, Pamplona, Spain
| | - Maite G Fernandez-Barrena
- IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), Spain; University of Navarra, Centre for Applied Medical Research, Hepatology Program, Pamplona, Spain
| | - Matthias Evert
- Institute of Pathology, University of Regensburg, Regensburg, Germany
| | | | - Diego F Calvisi
- Institute of Pathology, University of Regensburg, Regensburg, Germany
| | - Jesus M Banales
- Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute - Donostia University Hospital -, University of the Basque Country (UPV/EHU), San Sebastian, Spain; National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), Spain; Ikerbasque, Basque Foundation for Sciences, Bilbao, Spain
| | - Silve Vicent
- University of Navarra, Centre for Applied Medical Research, Program in Solid Tumours, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC, Instituto de Salud Carlos III), Madrid, Spain; University of Navarra, Department of Pathology, Anatomy and Physiology, Pamplona, Spain.
| |
Collapse
|